Recent Advances in Inflammation & Allergy Drug Discovery最新文献

{"title":"Clinical Insights into Protein-based Therapies for Precision Targeting of Psoriasis.","authors":"Krishna Yadav, R Vijayalakshmi, Kantrol Kumar Sahu, Sucheta, Kushagra Nagori, Deependra Singh, Manju Rawat Singh, Madhulika Pradhan","doi":"10.2174/0127722708331606250128063129","DOIUrl":"10.2174/0127722708331606250128063129","url":null,"abstract":"<p><p>Psoriasis (PsR), a chronic autoimmune disorder, affects millions of individuals globally and has a substantial impact on their quality of life. This complex condition involves intricate molecular networks and signaling pathways, making the development of effective treatments a significant challenge. Moreover, to advance treatment options, precise targeting of cells through the identification of protein biomarkers in PsR has emerged as a promising field of research for both fundamental and clinical scientists. These protein components provide valuable insights into the underlying mechanisms of the disease and can serve as indicators of treatment response. Furthermore, by identifying specific biocomponents, researchers can develop targeted therapeutics that address the molecular abnormalities driving PsR. The use of biologics as potential targets for improving treatment efficacy is a significant focus in PsR research. Biologics, which include monoclonal antibodies and fusion proteins, specifically target key molecules involved in the immune response, such as tumor necrosis factor-alpha (TNF-α) and interleukins (IL). These targeted therapies have demonstrated substantial efficacy in managing PsR by modulating the immune system and reducing inflammation. Recent advancements in moleculartargeted therapies utilizing biologics or small-molecule inhibitors have contributed to improving patient outcomes. This review aims to summarize the recent discoveries and insights regarding biocomponents and their importance in treating PsR, encompassing both its inflammatory and dermatological aspects. Furthermore, the review discusses the commercial outcomes of ongoing clinical trials for various biological-based therapeutic modalities for PsR, providing valuable insights into the evolving landscape of PsR therapeutics. These developments indicate the growing interest and investment in improving treatment options for individuals living with PsR.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"47-75"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of Chemotherapy-related Oral Mucositis by Topical Timolol: A Prospective Randomized, Double-blind, Placebo-controlled Clinical Trial in Cancer Patients.","authors":"Fatemeh Saghafi, Fatemeh Shaker-Ardakani, Mohsen Nabi-Meybodi, Hassan-Ali Vahedian-Ardakani, Adeleh Sahebnasagh","doi":"10.2174/0127722708312485250115052258","DOIUrl":"10.2174/0127722708312485250115052258","url":null,"abstract":"<p><strong>Background: </strong>Timolol is a beta-adrenergic blocker that has been shown to be effective in the healing of wounds. Oral mucositis (OM), an acute inflammation of the oral mucosa, is a bothersome side effect of some regimens of chemotherapy in which the oral mucosa becomes ulcerated. The current study aimed to evaluate the prophylactic effects of timolol mouthwash in preventing OM in adult patients receiving chemotherapy compared to the placebo.</p><p><strong>Methods: </strong>This randomized, double-blind trial was conducted on 30 adult patients receiving chemotherapy regimen, including doxorubicin or 5-fluorouracil (5-FU). The patients were randomized in a 1:1 ratio to receive either timolol 0.5% (w/v) (n = 15) or placebo (n = 15) mouthwash 5 ml three times per day. The outcomes of the study were the intensity of OM evaluated by the World Health Organization (WHO) mucositis scale and OM-related pain based on the Visual Analog Scale (VAS) weekly during the seven weeks of the study period.</p><p><strong>Results: </strong>The results of the study showed that the scores of WHO mucositis scale significantly decreased in the timolol group compared to the control group during the study [week 1: mean (SD), 0.02 (0.41) in the timolol group, and 0.67 (0.48) in the control group; week 7: mean (SD), 0.33 (0.61) in the timolol group, and 0.87 (0.74) in the control group; P-value = 0.049]. Moreover, the mean pain scores significantly decreased in the first, second, and third weeks in the timolol group compared to the control group (P-value < 0.05).</p><p><strong>Conclusion: </strong>The results of this preliminary clinical trial demonstrated that among the patients receiving doxorubicin or 5-FU chemotherapy regimens, the preventive use of timolol mouthwash significantly diminished the severity of OM compared to the control group during the seven weeks of follow-up. The severity of pain was also significantly lower during the first three weeks of the study; however, the effect size was less than the minimal clinically important difference. Further studies are required to assess both the long-term efficacy and safety of timolol mouthwash in preventing OM.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"89-99"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring New Horizons in Wound Healing: A Comprehensive Analysis.","authors":"Saurabh Punia, Dheeraj Upadhyay, Pratiksha Srivastava, Sandeep Kumar Maurya, Umesh Kumar Patil, Meenakshi Gupta","doi":"10.2174/0127722708343632250305034309","DOIUrl":"10.2174/0127722708343632250305034309","url":null,"abstract":"<p><p>The physiological process of wound healing is complicated and involves extensive connections between biological, molecular, and cellular pathways. Acute and chronic wounds possess a serious socioeconomic burden by impacting millions of people each year globally, which has significantly increased the problem of amputations, longer hospital stays, and mortality. Despite tremendous progress, in aging populations, associated conditions like diabetes and growing antibiotic resistance make chronic wounds even more clinically challenging. Recent developments in science, technology and research at cellular and molecular levels have opened up new possibilities for wound healing by laying the foundation for new technologies, techniques, and information. This review provides an in-depth knowledge of phases of wound healing, innovative methods, and combining technology for wound repair for successful therapies. This study reveals the associated challenges with wound healing dressings, including traditional, advanced, and biotechnology-based dressings. Moreover, this study also includes herbal remedies for wound repair, wound assessment techniques, and experimental wound healing models. This report additionally includes new treatment technologies, such as smart wound dressings capable of real-time monitoring and delivery of drugs at a controlled rate. Finally, an extremely inventive and futuristic approach that adds a new horizon in wound healing is the use of nanorobots, and new analytical tools based on machine learning and artificial intelligence (AI) are also considered.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"211-258"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alzheimer's Disease and Inflammation Research: A Systematic Bibliometric Review and Network Visualization of the Published Literature Between 2000 and 2023.","authors":"Khairunnuur Fairuz Azman, Che Aishah Nazariah Ismail, Nazlahshaniza Shafin, Rahimah Zakaria","doi":"10.2174/0127722708363344250529050252","DOIUrl":"10.2174/0127722708363344250529050252","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and memory loss. In recent years, inflammation has gained recognition as a key contributor to both the onset and progression of Alzheimer's disease, acting through complex pathways that include neuroinflammation and immune system dysregulation. This study aims to systematically review the relationship between Alzheimer's disease and inflammation, focusing on publication trends from 2000 to 2023.</p><p><strong>Methods: </strong>Using the Scopus database, a bibliometric analysis was conducted through Microsoft Excel, Harzing's Publish or Perish, and VOSviewer, examining publication trends, citation metrics, and co-network visualization.</p><p><strong>Results: </strong>A total of 1,205 relevant publications were identified, revealing a steady increase in research output. The majority of contributions came from the United States (33.1%), China (16.8%), and the United Kingdom (8.8%). Key terms such as \"neuroinflammation\", \"cytokine\", \"microglia\", \"amyloid beta\", and \"oxidative stress\" dominated the literature, while emerging keywords included \"neuroprotection\", \"BDNF\", \"inflammasome\", and \"mitochondria\".</p><p><strong>Conclusion: </strong>These findings underscore the growing focus on the role of inflammatory processes in the etiopathology of Alzheimer's disease, as well as efforts to identify biomarkers and neuroprotective therapeutic targets. This study provides a detailed mapping of the research landscape, offering insights into the evolving knowledge structure and highlighting prominent countries, institutions, authors, journals, and highly cited articles. By identifying key trends, this review advances our understanding of the interplay between inflammation and Alzheimer's disease, paving the way for future research and clinical strategies.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"259-275"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144286645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Bibliometric Analysis on Urticaria: Roles of Oxidative Stress, Inflammation, Immunity, and Treatment Modalities.","authors":"Hafiz Muhammad Zeeshan, Md Belal Bin Heyat, Arshiya Sultana, Mohd Ammar Bin Hayat, Eram Sayeed, Faijan Akhtar, Nouhayla Benkmil, Rashid Abbasi, Asmaa Sayed Abdelgeliel","doi":"10.2174/0127722708352247250121110712","DOIUrl":"10.2174/0127722708352247250121110712","url":null,"abstract":"<p><p>This study provides a comprehensive bibliometric analysis of global research on urticaria, aiming to chart its progression, assess its relevance, and explore the roles of oxidative stress, inflammation, and immunity in its pathogenesis. Additionally, by analyzing data from PubMed and Scopus, we mapped research trends, identified leading authors and institutions, and examined global collaboration patterns. We also evaluated the impact of oxidative stress, inflammation, and immunity on urticaria and assessed the roles of both conventional and traditional medicine in its management. The results highlight the evolution of urticaria research, key contributors, thematic developments, and collaborative networks. This study offers a detailed bibliometric profile and thematic map, including insights into effective authors, prominent keywords, and significant research patterns. The findings are valuable for medical researchers, providing an updated overview of current themes and gaps, and are also beneficial for healthcare decision-makers by summarizing relevant information for strategic planning and fostering new collaborations. Additionally, the study integrates biological aspects related to urticaria with insights into traditional treatments, contributing to both research and practical management strategies.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"17-46"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NF-κB in Drug Discovery: Still an Elusive Target.","authors":"Stefano Fiorucci, Ginevra Urbani","doi":"10.2174/0127722708490915260507065850","DOIUrl":"10.2174/0127722708490915260507065850","url":null,"abstract":"","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"201-205"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophilic Esophagitis and Lymphocytic Esophagitis: Convergent Symptoms, Divergent Biology.","authors":"Stefano Fiorucci, Elena Rondini, Eleonora Distrutti","doi":"10.2174/0127722708494346260507061541","DOIUrl":"10.2174/0127722708494346260507061541","url":null,"abstract":"","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"206-210"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Spectrum of Allergic Rhinitis: Risk Factors and their Clinical Relevance.","authors":"Hari Niwas, Priyanka Bansal, Bhavani Pentela, Avijit Mazumder","doi":"10.2174/0127722708397912251001102439","DOIUrl":"https://doi.org/10.2174/0127722708397912251001102439","url":null,"abstract":"<p><p>Allergic rhinitis (AR) is a common, chronic inflammatory disorder of the upper respiratory tract, primarily caused by exposure to environmental allergens such as pollen, dust mites, and mold. It has a substantial impact on daily life, often leading to sleep disruption, decreased productivity, and a heightened risk of asthma and other related conditions. The underlying mechanism of AR involves an IgE-mediated immune reaction, with both immediate and delayed inflammatory responses contributing to ongoing symptoms. AR can be classified into several types-seasonal, perennial, occupational, and drug-induced-which aids in its diagnosis and personalized management. Key risk factors include hereditary susceptibility, environmental pollution, and modern lifestyle factors. Diagnosis is typically based on a detailed medical history, skin prick testing, and serum IgE measurements. Treatment strategies involve the use of antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists, complemented by allergen-specific immunotherapy and lifestyle modifications such as allergen avoidance. In recent years, advanced therapies like targeted biologics (e.g., dupilumab) and probiotic-based treatments have emerged, offering promising new avenues for patients with persistent or severe symptoms.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of IL32 Variant rs45499297 with Gingivitis and IL-32 Levels: A Cross-sectional Clinical-bioinformatics Study.","authors":"Sonia Isela Vázquez-Jiménez, Luz Andrea Martínez-Perez, Julieta Saraí Becerra-Ruiz, Grecia Denisse González-Sánchez, Angel Perez-Reyes, Fernando Martínez Esquivias, Juan Manuel Guzmán-Flores","doi":"10.2174/0127722708418796251009203141","DOIUrl":"https://doi.org/10.2174/0127722708418796251009203141","url":null,"abstract":"<p><strong>Introduction: </strong>Gingivitis is the initial manifestation of periodontal disease, characterized by bacteria and inflammatory mediators, such as IL-32. This study aimed to determine whether the rs45499297 genetic variant of the IL32 gene and its serum and salivary levels are associated with gingivitis. In addition, we investigated whether transcription factors bind differentially in the presence of this genetic variant.</p><p><strong>Methods: </strong>The study was conducted with 147 subjects. The rs45499297 variant was analyzed using the PCR-RFLP technique, while cytokine levels were measured using the ELISA assay. The affinity of the transcription factors in the presence of the gene variant was analyzed using bioinformatics methods. The results suggest that schooling, salivary flow, lipids, and salivary IL-32 levels were associated with gingivitis. Furthermore, the TC genotype, in the presence of obesity, conferred an increased risk of gingivitis, which was associated with lower serum IL-32 levels. Bioinformatics analysis revealed that the transcriptional factor LRH1 binds with a higher affinity to the C allele than to the T allele of the studied genetic variant.</p><p><strong>Results: </strong>The findings of this study demonstrate the multifactorial nature of gingivitis, wherein the interplay between genetics and obesity serves as a regulatory factor in inflammation and periodontal risk. The preferential binding of LRH1 to the C allele suggests a molecular link between the genetic variant, inflammatory dysregulation, and the altered metabolic environment in obesity.</p><p><strong>Conclusion: </strong>Our data show that the rs45499297 gene variant is only associated with gingivitis in the presence of obesity and affects serum cytokine levels. Additionally, we identified the potential involvement of LRH1 in regulating the IL-32 gene expression.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apremilast in Psoriasis: Current Landscape and Perspectives.","authors":"Dinesh Kumar, Debayan Sil, Balak Das Kurmi, Manish Kumar","doi":"10.2174/0127722708351802250717104057","DOIUrl":"https://doi.org/10.2174/0127722708351802250717104057","url":null,"abstract":"<p><p>Psoriasis is an immune-mediated skin disease manifested in more than 3% of Americans and over 125 million people worldwide. The inflammatory skin condition with an increased rate of keratinocyte turnover involves every level of the skin and exhibits various forms of the disease, including plaque, guttate, inverse, pustular, and erythrodermic psoriasis, as well as disease-associated conditions, such as psoriatic arthritis and nail psoriasis. Innovative treatment has highlighted the importance of Apremilast, an oral drug that belongs to the phosphodiesterase- 4 (PDE4) class, which was approved by the FDA in 2014. Apremilast works by increasing the presence of cyclic adenosine monophosphate (cAMP) within cells, thereby affecting inflammatory processes and reducing the production of pathological cytokines. Randomized controlled trials have shown that it effectively treats moderately to severely affected plaque psoriasis and psoriatic arthritis, and it is safer than traditional systemic agents. The new perspective on the usage of ethosomes, niosomes, liposomes, and nanostructured lipid carriers in psoriasis treatment is based on emerging nanotechnology in drug delivery systems. These new formulations are designed to enhance the solubility and targeted release of Apremilast, thus providing an enhanced therapeutic effect. This review will discuss the basic mechanisms of the disease known as psoriasis, as well as the mode of operation, pharmacological properties, clinical trials, and pharmacokinetics of apremilast, particularly in relation to nanocarrier modification of this promising drug.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}